Item Type | Name |
Concept
|
Antibodies, Monoclonal
|
Concept
|
Antibodies, Antineutrophil Cytoplasmic
|
Concept
|
Antibodies, Monoclonal, Humanized
|
Concept
|
Antibodies
|
Concept
|
Antibodies, Antinuclear
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
Academic Article
|
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
|
Academic Article
|
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
|
Academic Article
|
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
|
Academic Article
|
Advances in the management of Crohn's disease: economic and clinical potential of infliximab.
|
Academic Article
|
Infliximab for the treatment of fistulas in patients with Crohn's disease.
|
Academic Article
|
Infliximab in Crohn's disease: first anniversary clinical experience.
|
Academic Article
|
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
|
Academic Article
|
Updating the approach to Crohn's disease.
|
Academic Article
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
|
Academic Article
|
Biologics in peri-operative management of Crohn's disease.
|
Academic Article
|
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
|
Academic Article
|
Evolutionary biologic therapy for inflammatory bowel disease.
|
Academic Article
|
Immunogenicity of infliximab in Crohn's disease.
|
Academic Article
|
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
|
Academic Article
|
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
|
Academic Article
|
Considerations in the management of steroid-dependent Crohn's disease.
|
Academic Article
|
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
|
Academic Article
|
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
|
Academic Article
|
Treatment of inflammatory bowel disease: safety and tolerability issues.
|
Academic Article
|
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
|
Academic Article
|
A lupus-like syndrome associated with infliximab therapy.
|
Academic Article
|
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
|
Academic Article
|
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
|
Academic Article
|
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
|
Academic Article
|
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
|
Academic Article
|
Natalizumab induction and maintenance therapy for Crohn's disease.
|
Academic Article
|
Emerging biologic therapies in inflammatory bowel disease.
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
Academic Article
|
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
|
Academic Article
|
Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease.
|
Academic Article
|
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
|
Academic Article
|
Refining the role of TNF antagonists for Crohn's disease. Introduction.
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
Academic Article
|
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
|
Academic Article
|
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
|
Academic Article
|
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
|
Academic Article
|
General principles and pharmacology of biologics in inflammatory bowel disease.
|
Academic Article
|
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
|
Academic Article
|
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
|
Academic Article
|
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
|
Academic Article
|
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
|
Academic Article
|
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
|
Academic Article
|
Maintenance therapy with certolizumab pegol for Crohn's disease.
|
Academic Article
|
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
|
Academic Article
|
Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis.
|
Academic Article
|
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
|
Academic Article
|
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
|
Academic Article
|
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
|
Academic Article
|
Treatment of inflammatory bowel disease: a review of medical therapy.
|
Academic Article
|
Management of inflammatory bowel disease: past, present and future.
|
Academic Article
|
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
|
Academic Article
|
Circulating lymphocyte subpopulations in Crohn's disease.
|
Academic Article
|
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.
|
Academic Article
|
Infliximab for induction and maintenance therapy for ulcerative colitis.
|
Academic Article
|
Practical application of anti-TNF therapy for luminal Crohn's disease.
|
Academic Article
|
What to take from TREAT?
|
Academic Article
|
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
|
Academic Article
|
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
|
Academic Article
|
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
|
Academic Article
|
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
|
Academic Article
|
pANCA and classification resistance in ulcerative colitis.
|
Academic Article
|
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
|
Academic Article
|
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
|
Academic Article
|
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
|
Academic Article
|
Review article: safety of infliximab in clinical trials.
|
Academic Article
|
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
|
Academic Article
|
Infliximab or cyclosporine for severe ulcerative colitis.
|
Academic Article
|
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
|
Academic Article
|
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
|
Academic Article
|
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
|
Academic Article
|
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.
|
Academic Article
|
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
|
Academic Article
|
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
|
Academic Article
|
Vedolizumab as induction and maintenance therapy for Crohn's disease.
|
Academic Article
|
Still in pursuit.
|
Academic Article
|
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
|
Academic Article
|
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
|
Academic Article
|
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
|
Academic Article
|
Briakinumab for treatment of Crohn's disease: results of a randomized trial.
|
Academic Article
|
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
|
Academic Article
|
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
|
Academic Article
|
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
|
Academic Article
|
Targeting Crohn's disease.
|
Academic Article
|
Checkpoint Inhibitor-Induced Colitis.
|
Academic Article
|
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
|
Academic Article
|
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
|
Academic Article
|
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
|
Academic Article
|
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
|
Academic Article
|
The importance of predicting patient responses to monoclonal antibodies for Crohn's disease.
|